Literature DB >> 9735394

Alteration of the CDKN2A gene in pancreatic cancers: Is it a late event in the progression of pancreatic cancer?

Y Sugimoto1, R Morita, K Hikiji, G Imura, Y Ogata, D Yasuda, A Kono, H Iguchi.   

Abstract

Various genetic changes are involved in progression of various cancers. We examined alterations (deletion, sequence abnormalities, methylation) of the CDKN2A gene in cell lines and tumor tissues of pancreatic cancers. Some alterations of this gene were found in all the 12 cell lines examined. In the primary lesions of pancreatic cancers, homozygous or hemizygous deletion were found in 8 of 24 ductal carcinoma and 4 of 9 other types of carcinomas. It appears that there is an association between the alteration of this gene and tumor size, regional lymph node metastasis and hematogenous distant metastasis in the ductal carcinoma, but not in the other types of carcinomas. All the 5 liver metastatic lesions of the ductal carcinoma examined revealed homozygous or hemizygous deletion and 3 bp deletion. These results suggest that inactivation of the CDKN2A gene occurs more frequently in cell lines than in pancreatic cancer tissues. Such genetic events on the CDKN2A gene may play an important role possibly at a later step in the progression of pancreatic ductal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9735394     DOI: 10.3892/ijo.13.4.669

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  2 in total

1.  Estimating the order of mutations during tumorigenesis from tumor genome sequencing data.

Authors:  Ahrim Youn; Richard Simon
Journal:  Bioinformatics       Date:  2012-04-06       Impact factor: 6.937

2.  Comprehensive Analysis Revealed that CDKN2A is a Biomarker for Immune Infiltrates in Multiple Cancers.

Authors:  Zheng Chen; Yingjie Guo; Da Zhao; Quan Zou; Fusheng Yu; Lijun Zhang; Lei Xu
Journal:  Front Cell Dev Biol       Date:  2021-12-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.